| Dr Robert Wood Byrd, MD | |
|
1725 Mcintosh St, Bowling Green, KY 42104-1037 | |
| (270) 793-9229 | |
| (270) 793-9076 |
| Full Name | Dr Robert Wood Byrd |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 30 Years |
| Location | 1725 Mcintosh St, Bowling Green, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801964630 | NPI | - | NPPES |
| 000000051792 | Other | KY | ANTHEM BCBS |
| 2500010452 | Other | KY | RR MEDICARE |
| 64343403 | Medicaid | KY | |
| 1159636 | Other | KY | PASSPORT MEDICAID |
| 2300063 | Other | KY | UMWA |
| 8201 | Other | KY | KENTUCKY WC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 34304 (Kentucky) | Primary |
| 208VP0000X | Pain Medicine - Pain Medicine | 34304 (Kentucky) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Medical Center (bowling Green) | Bowling green, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Interventional Pain And Spine Specialists, Llc | 4981036118 | 6 |
News Archive
Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.
As children's waistlines continue to grow, so have concerns about childhood obesity. According to a report released today by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health, childhood obesity is now the No. 1 health concern for kids in 2008, topping smoking and drug abuse. In 2007, childhood obesity ranked third among parents' top 10 overall health concerns for kids.
The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.
Imagenetix, Inc., announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.
› Verified 8 days ago
| Entity Name | Pain Management Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063831303 PECOS PAC ID: 0143453670 Enrollment ID: O20140507000797 |
News Archive
Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.
As children's waistlines continue to grow, so have concerns about childhood obesity. According to a report released today by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health, childhood obesity is now the No. 1 health concern for kids in 2008, topping smoking and drug abuse. In 2007, childhood obesity ranked third among parents' top 10 overall health concerns for kids.
The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.
Imagenetix, Inc., announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.
› Verified 8 days ago
| Entity Name | Robert Byrd Md, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639629389 PECOS PAC ID: 0941589931 Enrollment ID: O20161115001613 |
News Archive
Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.
As children's waistlines continue to grow, so have concerns about childhood obesity. According to a report released today by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health, childhood obesity is now the No. 1 health concern for kids in 2008, topping smoking and drug abuse. In 2007, childhood obesity ranked third among parents' top 10 overall health concerns for kids.
The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.
Imagenetix, Inc., announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.
› Verified 8 days ago
| Entity Name | Interventional Pain & Spine Specialists, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861182198 PECOS PAC ID: 4981036118 Enrollment ID: O20191108002414 |
News Archive
Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.
As children's waistlines continue to grow, so have concerns about childhood obesity. According to a report released today by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health, childhood obesity is now the No. 1 health concern for kids in 2008, topping smoking and drug abuse. In 2007, childhood obesity ranked third among parents' top 10 overall health concerns for kids.
The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.
Imagenetix, Inc., announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Wood Byrd, MD 1310 New Cut Rd, Bowling Green, KY 42103-8404 Ph: (270) 783-4202 | Dr Robert Wood Byrd, MD 1725 Mcintosh St, Bowling Green, KY 42104-1037 Ph: (270) 793-9229 |
News Archive
Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.
As children's waistlines continue to grow, so have concerns about childhood obesity. According to a report released today by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health, childhood obesity is now the No. 1 health concern for kids in 2008, topping smoking and drug abuse. In 2007, childhood obesity ranked third among parents' top 10 overall health concerns for kids.
The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.
Imagenetix, Inc., announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.
› Verified 8 days ago
Emma Ramsey, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1751 Scottsville Rd Ste 9, Bowling Green, KY 42104 Phone: 270-796-6800 | |
Dr. James Robert Farrage Jr., M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1725 Mcintosh St, Bowling Green, KY 42104 Phone: 270-793-9229 Fax: 270-793-9076 | |
Dr. Pamela Kaye Harston, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1890 Lyda Ave, Suite 103, Bowling Green, KY 42104 Phone: 270-904-6160 Fax: 270-904-6165 |